# Ad26.COV2.S as a Heterologous Booster in Adults After Single- or Two-Dose of Inactivated COVID-19 Vaccine

> **NCT05109559** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Mahidol University** · enrollment: 690 (estimated)

## Conditions studied

- SARS-CoV-2 Infection

## Interventions

- **BIOLOGICAL:** Full dose of Ad26.COV2. 5x10^10vp
- **BIOLOGICAL:** Half dose of Ad26.COV2. 2.5x10^10vp
- **BIOLOGICAL:** Full dose of Ad26.COV2. 5x10^10vp

## Key facts

- **NCT ID:** NCT05109559
- **Lead sponsor:** Mahidol University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-20
- **Primary completion:** 2023-12
- **Final completion:** 2024-12
- **Target enrollment:** 690 (ESTIMATED)
- **Last updated:** 2022-09-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05109559

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05109559, "Ad26.COV2.S as a Heterologous Booster in Adults After Single- or Two-Dose of Inactivated COVID-19 Vaccine". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05109559. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*